Eli Lilly's experimental drug shows promising results in slowing Alzheimer's progression.

Eli Lilly's experimental Alzheimer's drug, donanemab, slowed cognitive decline by 35% in a late-stage trial, meeting all goals of the study. The drug slowed progression of Alzheimer's by 35% to 36% compared to a placebo in 1,182 people diagnosed with early-stage disease based on scans showing brain deposits of amyloid protein and intermediate levels of tau protein. The drug is likely to become the third in its class on the market following U.S. approval of two similar medicines developed by partners Eisai and Biogen - Leqembi and Aduhelm.